In 2023, Guangdong Sanggu Medical Robot Co., Ltd. was established.
In 2022, the product was introduced to Peking University Cancer Hospital.
In 2021, the product was introduced to the Second Xiangya Hospital of Central South University.
Successfully installed and put into clinical application in the first hospital in Shenzhen.
The newly developed seventh-generation IDOLPHIN7 was launched.
1. Awarded the title of "Council Member Unit" by the Hunan Provincial Enterprise Science and Technology Association Federation.
2. Awarded the title of High-tech Enterprise.
3. Established robot application centers with multiple hospitals.
The sixth-generation drug compounding robot IDOLPHIN 6 was launched and put into clinical application, receiving positive evaluations.
1. Han's Laser Technology Industry Group Co., Ltd. made an equity investment.
2. The fourth and fifth generations of IDOLPHIN were launched.
1. The wholly-owned subsidiary "Hengyang Sanggu Medical Robot Co., Ltd." was established with a registered capital of 70 million yuan.
2. The third-generation IDOLPHIN was launched.
In collaboration with Unmaion (USA), the Shenzhen Branch of the Chinese Academy of Sciences, Peking University Shenzhen Hospital, and the Affiliated Hospital of Southern Medical University, the second-generation intravenous drug compounding robot IDOLPHIN was launched.
1. In 2013, the first prototype of the "Mobile Intelligent Intravenous Drug Compounding Robot" was born.
2. In the same year, the company was renamed "Shenzhen Sanggu Medical Robot Co., Ltd." and obtained multiple patent certificates, including "Fully Functional Intelligent Liquid Drug Compounding Robot and Compounding Method."
Shenzhen Sanggu Technology Co., Ltd. was established
WeChat QR code
